InDex Pharmaceuticals Holding AB banner
I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 35 SEK -0.71% Market Closed
Market Cap: kr2.7B

Relative Value

The Relative Value of one FLERIE stock under the Base Case scenario is 0.19 SEK. Compared to the current market price of 35 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 99%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FLERIE Relative Value
Base Case
0.19 SEK
Overvaluation 99%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Multiples Across Competitors

FLERIE Competitors Multiples
InDex Pharmaceuticals Holding AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
InDex Pharmaceuticals Holding AB
STO:FLERIE
2.7B SEK 0 -3.6 -67 -67
US
Eli Lilly and Co
NYSE:LLY
986.4B USD 15.1 47.7 32.2 34.2
US
Johnson & Johnson
NYSE:JNJ
586.1B USD 6.2 21.9 15.2 18.6
CH
Roche Holding AG
SIX:ROG
286.3B CHF 4.7 30.5 12.9 15
UK
AstraZeneca PLC
LSE:AZN
235.3B GBP 5.5 31.3 17.3 24.3
CH
Novartis AG
SIX:NOVN
239B CHF 5.5 22 13.6 17.4
US
Merck & Co Inc
NYSE:MRK
301.2B USD 4.6 16.5 10.3 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.5 9.9 11.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
157.3B USD 2.5 20.2 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
123.4B USD 2.6 17.5 6.8 8.8
P/E Multiple
Earnings Growth PEG
SE
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Average P/E: 24.6
Negative Multiple: -3.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.7
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.5
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.3
26%
1.2
CH
Novartis AG
SIX:NOVN
22
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Average EV/EBITDA: 45.9
Negative Multiple: -67
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.3
11%
1.6
CH
Novartis AG
SIX:NOVN
13.6
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Average EV/EBIT: 98.7
Negative Multiple: -67
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.2
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
24.3
24%
1
CH
Novartis AG
SIX:NOVN
17.4
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-6%
N/A